OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
IRVINE, Calif., June 09, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Intra-Cellular Therapies, Inc. (“Intra-Cellular” or the “Company”) (Nasdaq:ITCI). Investors who purchased or otherwise acquired shares between August 12, 2014 and April 28, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the July 11, 2017 lead plaintiff motion deadline.
If you purchased shares of Intra-Cellular during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or via e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Intra-Cellular made false and/or misleading statements and/or failed to disclose: that findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; that these findings posed an additional safety concern regarding lumateperone; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On August 4, 2016, the Company’s Chief Executive Officer, Sharon Mates, touted the “efficacy and safety of ITI-007 for the treatment of schizophrenia.” On May 1, 2017, Intra-Cellular disclosed that the U.S. Food and Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long term exposure of ITI-007 to patients. Upon release of this information to the public, Intra-Cellular’s stock price fell materially, which harmed investors according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
